Monday Mar 3
Myriad publishes clinical utility study for Prolaris
Myriad Genetics, Inc. today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion , demonstrating that 65 percent of physicians changed their original treatment plans for men with prostate cancer based on results from the Prolaris test.
Myriad Genetics Director Walter Phd Gilbert Unloads 30,000 Shares
Myriad Genetics Director Walter Phd Gilbert unloaded 30,000 shares of the stock in a transaction dated Wednesday, February 26th.
Settlement reached in Myriad Genetics' patent dispute with Houston company
Houston-based Gene by Gene Ltd. and Salt Lake City-based Myriad Genetics Inc. have reached an agreement to settle litigation regarding gene-related patents.
Insider Selling: Mark Christopher Capone Unloads 87,500 Shares of Myriad Genetics Stock
Myriad Genetics Insider Mark Christopher Capone unloaded 87,500 shares of the company's stock on the open market in a transaction dated Monday, February 10th.
Myriad Genetics Upgraded by Credit Suisse to "Neutral"
The firm currently has a $29.00 target price on the stock. Credit Suisse's price objective indicates a potential downside of 10.02% from the stock's previous close.
Wall St. Cheat Sheet
Myriad Genetics Reaches Settlement with Houston-Based Gene by Gene
Myriad Genetics Inc. and its affiliates have reached a settlement in a lawsuit against Gene by Gene Ltd. , a Houston-based company, over genetic testing for the BRCA1 and BRCA2 genes, mutations of which can indicate a high risk of breast and ovarian cancer , according to the Salt Lake Tribune .